Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous IL-2 Plus Antiretroviral Therapy in HIV
NCT00000825Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- May 1998
- Primary completion
- Mar 2000
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of aldesleukin in human immunodeficiency virus infection (HIV) (4 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Safety and Tolerability. Started May 1998; status: completed.
02
Drugs
aldesleukin
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00000825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00000825.